Scholarlink

Introduction <p>Talazoparib is a strong PARP inhibitor with significant catalytic inhibition as well as the ability to cause PARP entrapment at DNA damage sites. It is one of the recommended treatments for individuals with BRCA-mutant advanced breast cancer, although research on its efficacy in advanced ovarian cancer is limited. The purpose of this study was to evaluate the efficacy of talazoparib in advanced breast and ovarian cancer patients with BRCA mutations.</p> Materials and methods <p>Patients with advanced breast (HR + or TNBC) and ovarian cancer who had germline BRCA mutations were included in this multicenter, retrospective study. There were no exclusion criteria regarding treatment-line, metastatic sites or performance status. All patients received talazoparib treatment via early-access programme. The primary endpoint was PFS. Secondary endpoints were OS and ORR.</p> Results <p>There were 47 and 42 patients in the breast cancer (BC) and ovarian cancer (OC) cohorts, respectively. In BC cohort, after median 13.6 months follow-up the median PFS was 6.5 months (5.0–8.1 months, 95% CI). In this heavily pretreated cohort, the ORR was 31.9% and the estimated 12-month OS rate was 73.6%. In OC cohort, the median follow up period was 13.7 months and the median PFS was 9.1 months (7.3–10.8 months, 95% CI). The ORR was 47.6% and the estimated 12-month OS rate was 75.9% in OC patients.</p> Conclusion <p>Talazoparib may be an effective therapy option for patients with advanced BRCA-mutant breast cancer. In the absence of prospective phase 2/3 data, the outcomes of OC cohort may also considerably contribute to the literature on BRCA-mutant ovarian cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月22日

查看全文
  • Mehmet Ali Nahit Sendur,
  • Mutlu Hizal,
  • Burcu Çakar,
  • Oktay Halit Aktepe,
  • Emrah Eraslan,
  • Zafer Arık,
  • İsmail Erturk,
  • Sercan Aksoy,
  • Semra Paydaş,
  • Serkan Değirmencioğlu,
  • Cihan Erol,
  • Necla Demir,
  • Gülcan Bulut,
  • Naziye Ak,
  • Metin Özkan,
  • Alper Sevinç,
  • Nuriye Özdemir,
  • Umut Dişel,
  • Deniz Tural,
  • Mehmet Artaç,
  • Hacı Mehmet Türk,
  • Serkan Menekşe,
  • Sema Sezgin Göksu,
  • Fatih Köse,
  • Cağlayan Geredeli,
  • Meral Günaldı,
  • Başak Oyan Uluç,
  • Fatma Şen,
  • Kerem Oruç,
  • Ömer Fatih Ölmez,
  • Abdullah Sakin,
  • Umut Demirci,
  • Dilek Erdem,
  • Ferhat Ekinci,
  • Nihat Ökten,
  • Leyla Özer,
  • Kerem Okutur,
  • Atakan Demir,
  • Nuri Karadurmuş,
  • Muhammed Bülent Akıncı,
  • Bülent Yalçın,
  • Erhan Gökmen

摘要

Introduction

Talazoparib is a strong PARP inhibitor with significant catalytic inhibition as well as the ability to cause PARP entrapment at DNA damage sites. It is one of the recommended treatments for individuals with BRCA-mutant advanced breast cancer, although research on its efficacy in advanced ovarian cancer is limited. The purpose of this study was to evaluate the efficacy of talazoparib in advanced breast and ovarian cancer patients with BRCA mutations.

Materials and methods

Patients with advanced breast (HR + or TNBC) and ovarian cancer who had germline BRCA mutations were included in this multicenter, retrospective study. There were no exclusion criteria regarding treatment-line, metastatic sites or performance status. All patients received talazoparib treatment via early-access programme. The primary endpoint was PFS. Secondary endpoints were OS and ORR.

Results

There were 47 and 42 patients in the breast cancer (BC) and ovarian cancer (OC) cohorts, respectively. In BC cohort, after median 13.6 months follow-up the median PFS was 6.5 months (5.0–8.1 months, 95% CI). In this heavily pretreated cohort, the ORR was 31.9% and the estimated 12-month OS rate was 73.6%. In OC cohort, the median follow up period was 13.7 months and the median PFS was 9.1 months (7.3–10.8 months, 95% CI). The ORR was 47.6% and the estimated 12-month OS rate was 75.9% in OC patients.

Conclusion

Talazoparib may be an effective therapy option for patients with advanced BRCA-mutant breast cancer. In the absence of prospective phase 2/3 data, the outcomes of OC cohort may also considerably contribute to the literature on BRCA-mutant ovarian cancer.